The Asian Medical Technology Innovation Forum (MedTex 2025) will officially kick off on December 3. The organizer, the Institute for Biotechnology and Medicine Industry (IBMI), announced on the 17th that the event will bring six world-class international capital firms and ten globally recognized biotech startups to Taiwan. Under the theme “Medical Innovation and Global Investment Strategies in the AI Era,” the forum will engage Taiwan in one of the most forward-looking dialogues to date.
According to IBMI, AI is not only driving sweeping changes across the global technology landscape, but is also reshaping the blueprint of medical development. At this time of rapid transformation, what new opportunities are global benchmark venture capital firms identifying, and which high-potential targets are they betting on? Meanwhile, how are world-class startups riding the AI wave turning new technologies into proprietary advantages, and what innovations and business opportunities are they bringing to medicine? This year’s MedTex forum will unveil the key trends that Taiwanese investors and the biomedical industry must grasp.
IBMI noted that while Taiwan possesses strong biomedical research capabilities, it faces challenges such as a relatively small market size and limited patient pools for clinical trials, making technology translation and commercialization difficult. To upgrade and scale, international expansion is essential, along with deeper connections to top global venture capital firms and industry leaders. However, international integration is no easy task, and identifying the right partners is critical. Now in its eighth year, MedTex has taken on this mission by building an interactive platform connecting domestic and international stakeholders.
Building on years of experience through the National Innovation Award, its deep understanding of domestic biotech startup trends, and long-term observation of global capital flows and innovation dynamics, IBMI, the Research Center for Biotechnology and Medicine Policy (RBMP), and Everbright Biofund are leveraging MedTex to connect Taiwanese capital and research teams with global leaders. This year, six major international venture capital firms from Europe, the United States, and Israel—collectively managing assets exceeding NT$8 trillion—will participate, alongside ten AI-driven medical startups gaining global traction, sharing cutting-edge technologies with strong market potential.
Among the participating venture capital firms is Novo Holdings, the parent company of Danish pharmaceutical giant Novo Nordisk and the world’s largest life science investment group. With assets under management of approximately NT$4.8 trillion, Novo Holdings has invested in 181 biotech companies worldwide and achieved successful exits in 63 cases. Its partner, Noel Jee, will travel to Taiwan to publicly share the firm’s investment strategies and the technologies it sees as offering the greatest commercial potential.
The ten startups coming to Taiwan are all key targets of international capital deployment, with technologies spanning novel drug development, medical robotics, and breakthrough therapies. These include AI-driven drug discovery company Iambic, backed by NVIDIA and the Qatar Investment Authority, which developed a novel small-molecule anticancer drug and advanced it to Phase I clinical trials in just two years—compared with an industry average of five years. Another example is Swiss startup Nanoflex Robotics, which has developed a magnetically controlled cardiovascular interventional robot capable of remotely removing blood clots two to four times faster than conventional surgery, and has completed the world’s first remote (U.S. to Switzerland) animal thrombectomy trial this year.
Allen Wu, General Manager of Everbright Biofund, stated that Taiwan’s biomedical technologies continue to advance, positioning the country not only as a follower on the global stage, but also as a “co-creator.” MedTex, he emphasized, is the most important platform supporting such co-creation between Taiwan and international partners. Trends in domestic and global capital flows and key biomedical technology market hotspots for 2026 will be fully unveiled at the MedTex forum on December 3.
Resource: MedTex 2025於12月3日登場 六大國際級資本家、十家全球生技新創來台
